PMID- 32480407
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210602
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 8
DP  - 2020 Aug 1
TI  - Associations of Per- and Polyfluoroalkyl Substances (PFAS) With Glucose Tolerance 
      During Pregnancy in Project Viva.
PG  - e2864-76
LID - dgaa328 [pii]
LID - 10.1210/clinem/dgaa328 [doi]
AB  - CONTEXT: Per- and polyfluoroalkyl substances (PFAS) exposure may alter glucose 
      homeostasis. Research on PFAS exposure and glucose tolerance during pregnancy is 
      limited. OBJECTIVE: The objective of this work is to estimate associations 
      between first-trimester plasma PFAS concentrations and glucose tolerance assessed 
      in late second pregnancy trimester. DESIGN, SETTING, PARTICIPANTS, AND MAIN 
      OUTCOME MEASURES: Pregnant women (n = 1540) enrolled in Project Viva in 1999 to 
      2002 provided first-trimester plasma samples analyzed for 8 PFAS. At 
      approximately 28 weeks' gestation, women completed 1-hour nonfasting, 50-g oral 
      glucose challenge tests (GCTs); if abnormal, women completed subsequent 3-hour 
      oral glucose tolerance tests (OGTTs) to screen for gestational diabetes mellitus 
      (GDM). We assessed both continuous GCT glucose levels and 4 categories of glucose 
      tolerance (normal glycemia [reference], isolated hyperglycemia, impaired glucose 
      tolerance, GDM). We used multinomial logistic regression to estimate associations 
      of PFAS with glucose tolerance categories. We used multivariable linear 
      regression and Bayesian kernel machine regression (BKMR) to assess individual and 
      joint effects of PFAS on continuous GCT glucose levels, respectively. We 
      evaluated effect modification by maternal age and race/ethnicity. RESULTS: PFAS 
      were not associated with glucose tolerance categories. In BKMR analyses, we 
      observed a positive association between ln-perfluorooctane sulfonate (PFOS) and 
      glucose levels (Delta25th to 75th percentile: 6.2 mg/dL, 95% CI, 1.1-11.3) and an 
      inverse-U shaped association between 2-(N-perfluorooctane sulfonamide) acetate 
      and glucose levels. Individual linear regression results were similar. We found 
      suggestive evidence that associations varied by age and racial/ethnic group. 
      CONCLUSION: Certain PFAS may alter glucose homeostasis during pregnancy, but may 
      not be associated with overt GDM.
CI  - (c) Endocrine Society 2020. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Preston, Emma V
AU  - Preston EV
AD  - Department of Environmental Health, Harvard T.H. Chan School of Public Health, 
      Boston, Massachusetts.
FAU - Rifas-Shiman, Sheryl L
AU  - Rifas-Shiman SL
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim 
      Health Care Institute, Boston, Massachusetts.
FAU - Hivert, Marie-France
AU  - Hivert MF
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim 
      Health Care Institute, Boston, Massachusetts.
AD  - Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Zota, Ami R
AU  - Zota AR
AD  - Department of Environmental and Occupational Health, Milken Institute School of 
      Public Health, George Washington University, Washington, DC.
FAU - Sagiv, Sharon K
AU  - Sagiv SK
AD  - Center for Environmental Research and Children's Health, School of Public Health, 
      University of California at Berkeley, Berkeley, California.
FAU - Calafat, Antonia M
AU  - Calafat AM
AD  - U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
FAU - Oken, Emily
AU  - Oken E
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim 
      Health Care Institute, Boston, Massachusetts.
FAU - James-Todd, Tamarra
AU  - James-Todd T
AD  - Department of Environmental Health, Harvard T.H. Chan School of Public Health, 
      Boston, Massachusetts.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
      Massachusetts.
LA  - eng
GR  - UH3 OD023286/OD/NIH HHS/United States
GR  - R01 ES026166/ES/NIEHS NIH HHS/United States
GR  - T32 ES007069/ES/NIEHS NIH HHS/United States
GR  - R01 ES021447/ES/NIEHS NIH HHS/United States
GR  - R01 HD034568/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Fluorocarbons)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - Diabetes, Gestational/blood/*chemically induced/diagnosis/*epidemiology
MH  - Environmental Pollutants/adverse effects/*blood
MH  - Female
MH  - Fluorocarbons/adverse effects/*blood
MH  - Glucose Intolerance/blood/chemically induced/diagnosis/*epidemiology
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Longitudinal Studies
MH  - Pregnancy
MH  - Pregnancy Trimester, First/blood
MH  - Pregnancy Trimester, Second/blood
PMC - PMC7320827
OTO - NOTNLM
OT  - PFAS
OT  - gestational diabetes
OT  - impaired glucose tolerance
OT  - metabolic disruptors
OT  - pregnancy glucose
EDAT- 2020/06/02 06:00
MHDA- 2021/02/09 06:00
PMCR- 2021/06/01
CRDT- 2020/06/02 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2021/06/01 00:00 [pmc-release]
AID - 5849987 [pii]
AID - dgaa328 [pii]
AID - 10.1210/clinem/dgaa328 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2864-76. doi: 10.1210/clinem/dgaa328.